Reyataz + Norvir

Raw research findings for this medication. Mostly single studies, not curated or confirmed robust.

About Reyataz + Norvir

What it is

It is taken with other HIV medicines. The two are sold as Reyataz and Norvir; atazanavir is also combined with cobicistat as Evotaz.

How genes come into it

Atazanavir blocks UGT1A1, the liver enzyme that clears bilirubin, so bilirubin often rises and can turn the skin and eyes yellow; this is harmless to the liver but a common reason people stop. People with two low-activity UGT1A1 copies (*28/*28, the Gilbert's syndrome genotype) are much more likely to develop visible jaundice, a finding rated at PharmGKB's highest level. CPIC and DPWG have published guidelines on UGT1A1 and atazanavir, on its own page.

What research found

Every published finding on gene variants and Reyataz + Norvir. Upload your DNA file to see which of these rows apply to you.

Rated evidence (1 rated variant)

PharmGKB weighs all studies of a variant and rates how strong the evidence is, from 1A (strongest) to 4.

UGT1A1 UGT1A1*1, UGT1A1*6, UGT1A1*28, UGT1A1*36, UGT1A1*37: Level 1A · replicated. Toxicity: HIV infectious disease, Hyperbilirubinemia. 17.

Metabolism (2 findings)

Studies of how quickly the body processes this medication.

CYP3A5 rs776746: Genotype CC is associated with increased concentrations of atazanavir / ritonavir in people with HIV Infections as compared to genotypes CT + TT.

SLCO1B1 rs4149056: Genotypes CC + CT is associated with increased concentrations of atazanavir / ritonavir in people with HIV Infections as compared to genotype TT.

Side effects (3 findings)

Studies of side effects in people carrying a variant.

UGT1A1 UGT1A1*1, UGT1A1*28: UGT1A1 *28/*28 is associated with increased discontinuation of atazanavir / ritonavir in people with HIV Infections as compared to UGT1A1 *1/*1.

UGT1A1 UGT1A1*1, UGT1A1*28, UGT1A1*36: UGT1A1 *28/*28 is associated with increased discontinuation of atazanavir / ritonavir in people with HIV Infections as compared to UGT1A1 *1/*1 + *1/*28 + *1/*36 + *36/*36.

UGT1A1 UGT1A1*1, UGT1A1*28: UGT1A1 *1/*28 is not associated with increased discontinuation of atazanavir / ritonavir in people with HIV Infections as compared to UGT1A1 *1/*1.

Study findings and evidence levels: PharmGKB (CC BY-SA 4.0). Guidelines: CPIC and DPWG, as bundled in PharmCAT. Most studies were done mainly in people of European ancestry.

Related Drugs

More drugs from the same category

Agenerase (Protease Inhibitors)

Crixivan (Protease Inhibitors)

Kaletra (Protease Inhibitors)

Not a prescribing recommendation. This page is educational information about pharmacogenomic research and clinical guidelines - it is not medical or dosing advice, and not a prediction of how any medication will work for you. Never start, stop, or change a medication or dose based on it; talk to your doctor or pharmacist, who can order clinical-grade testing if appropriate.

Back to Medications

Content updated September 2026.

ReadYourDNA provides educational interpretation of DNA data you already have. It is not diagnostic, not a substitute for professional medical advice, diagnosis, or treatment, and is not intended to diagnose, treat, cure, or prevent any disease. Talk to a clinician before acting on any result.

Raw DNA Data Reports for 23andMe & AncestryDNA · About ReadYourDNA · FAQ · Methodology & Science · Pricing · Support and complaints · Legal & Contact · Health Traits · Pharmacogenomics · Carrier Status · Variant Explorer · The Human Karyotype · Privacy Policy · Terms of Service · Accessibility · Consumer Health Data Privacy · Your Privacy Choices · Editorial Standards · Your Data, Checkable · Sample Report · ReadYourDNA and Promethease compared · What is inside a 23andMe raw data file · What is inside an AncestryDNA raw data file · What a chatbot can and cannot do with your raw DNA file · Where a raw DNA file can still be uploaded in 2026

Written, maintained and operated by Martin Pechhacker, sole proprietor, Vienna, Austria. Trade register GISA 40064420. support@readyourdna.com